CareDx, Inc. (CDNA)

NASDAQ: CDNA · USD

$72.1

+1.62 (+2.3%)· Recorded snapshot

Market cap	3.7B
Revenue (ttm)	458.1M
Net income (ttm)	111M
EPS (ttm)	$2.12
Shares out	51.7M
P/E (trailing)	34.0x
P/E (forward)	67.5x
Volume	778,599
Beta	2.38

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 458.1M
Net income (ttm): 111M
EPS (ttm): $2.12
P/E (trailing): 34.0x
P/E (forward): 67.5x
Market cap: 3.7B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	持有

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E67.5

P25 n/aP50 n/aP75 n/a

Trailing P/E34

P25 n/aP50 n/aP75 n/a

ROE29.5

P25 n/aP50 n/aP75 n/a

ROIC-1.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CDNA indicators

Market & fundamental data

Available fields

249

Groups with data

Currency

USD

Showing 249 of 249 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001217234
Company name	CareDx, Inc.
Country	United States
Country code	US
CUSIP number	14167L103
Earnings date	2026-10-29
Earnings time	amc
Employees	765
Employees change	115
Employees growth	17.69%
Enterprise value	$3.4B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1998
In index	RUSSELL2000
Industry	Diagnostics & Research
IPO date	2014-07-17
Is primary listing	Yes
Is SPAC	No
ISIN number	US14167L1035
Last 10-K release date	2026-02-25
Last earnings date	2026-07-30
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$3.7B
Market cap category	Mid-Cap
Next earnings date	2026-10-29
Options	Yes
Price	$72.15
Price currency	USD
Sector	Healthcare
SIC code	8071
Stock price date	2026-10-28
Symbol	CDNA
U.S. state	California
Website	https://caredx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	65x
Earnings yield	2.94%
EV/Earnings	30.63x
EV/EBITDA	273.46x
EV/FCF	40.14x
EV/Sales	7.42x
FCF / EV yield	2.49%
FCF yield	2.26%
Forward EV/Sales	6.81x
Forward P/E	67.46x
Forward P/S	7.52x
Graham number	19.85858
Graham upside	-72.64%
Industry forward P/E	30.87x
Industry P/E	50.24x
P/(FCF - SBC) ratio	78.64x
P/(OCF - SBC) ratio	66.22x
P/B ratio	8.53x
P/E ratio	34.03x
P/FCF ratio	44.32x
P/OCF ratio	40.09x
P/S ratio	8.2x
Price / tangible book value	10.12x
Price/EBITDA ratio	301.97x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-0.43%
EBITDA margin	2.71%
Effective tax rate	3.63%
FCF margin	18.49%
Gross margin	70.58%
Operating margin	-0.43%
Pretax margin	25.15%
Profit margin	24.23%
Profit per employee	$145,114
Profitable quarters	2
Revenue per employee	$598,809
ROA	-0.25%
ROA (5Y)	-7.27%
ROCE	-0.45%
ROE	29.49%
ROE (5Y)	-14.03%
ROIC	-1.71%
ROIC (5Y)	-47.3%
SBC / revenue	8.07%
Tax / revenue	0.91%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	112.54%
EPS growth (QoQ)	4,040.08%
EPS growth quarters	2
EPS growth years	0
FCF growth	613.13%
FCF growth (Q)	223.43%
FCF growth (QoQ)	5,492.61%
Gross profit growth	41.82%
Gross profit growth (Q)	67.15%
Gross profit growth 3Y	17.43%
Gross profit growth 5Y	13.41%
Net income growth	90.94%
Net income growth (QoQ)	3,838.63%
Net income growth quarters	2
Net income growth years	0
OCF growth	428.48%
OCF growth (Q)	209.29%
OCF growth (QoQ)	606.3%
OCF growth 3Y	595.83%
Revenue growth	34.41%
Revenue growth (Q)	52.23%
Revenue growth (QoQ)	12.11%
Revenue growth 10Y	30.86%
Revenue growth 3Y	13.99%
Revenue growth 5Y	12.55%
Revenue growth quarters	4
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-9M
Depreciation and amortization	$14.4M
EBIT	$-2M
EBITDA	$12.4M
EPS	$2.12
FCF per share	$1.64
Financing cash flow	$-57.3M
Free cash flow	$84.7M
Free cash flow minus SBC	$47.7M
Gross profit	$323.3M
Income taxes	$4.2M
Investing cash flow	$269.1M
Net cash flow	$305.4M
Net income	$111M
Operating cash flow minus SBC	$56.7M
Operating income	$-2M
Revenue	$458.1M
Stock-based compensation	$37M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.49
Book value per share	$8.27
Debt / EBITDA	0.97
Debt / equity	0.05
Debt / FCF	0.23
Goodwill	$36M
Long-term assets	$103.8M
Long-term liabilities	$13.7M
Net cash (debt)	$354.4M
Net cash / market cap	9.44%
Net cash growth	125.53%
Net debt / EBITDA	-28.5
Net debt / equity	-0.83
Net debt / FCF	-4.18
Piotroski F-Score	5
Property, plant and equipment	$43M
Shareholders' equity	$425.6M
Tangible book value	$371.1M
Tangible book value per share	$7.21
Total assets	$533M
Total cash	$373.6M
Total debt	$19.2M
Total liabilities	$107.4M
WACC	17.27%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.94
Current assets	$429.2M
Current liabilities	$93.7M
Current ratio	4.58
Inventory turnover	7.72
Net working capital	$-32.1M
Quick ratio	4.35
Working capital	$335.5M
Working capital turnover	1.67

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	9.45%
Dividend yield	0%
Shareholder yield	9.45%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	1,784.68%
10Y return CAGR	34.14%
10Y total return	1,784.68%
150-day SMA	$37.70
1D price change	2.29%
1M price change	13.95%
1M total return	13.95%
1W price change	4.86%
1W total return	4.86%
1Y price change	400.07%
1Y return CAGR	400.62%
1Y total return	400.07%
20-day SMA	$66.87
200-day SMA	$33.05
3M price change	99.56%
3M total return	99.56%
3Y price change	1,351.2%
3Y return CAGR	143.87%
3Y total return	1,351.2%
50-day SMA	$58.63
50-day SMA vs 200-day SMA	50over200
52-week high	$73.43
52-week high date	2026-10-28
52-week low	$14.23
52-week low date	2025-10-30
5Y price change	7.64%
5Y return CAGR	1.48%
5Y total return	7.64%
6M price change	232.08%
6M total return	232.08%
All-time high	$99.83
All-time high date	2021-01-20
All-time low	$0.76
All-time low date	2017-04-28
Average true range (ATR)	$3.84
Average volume	1.3M
Beta (1Y)	0.6
Beta (2Y)	0.92
Beta (5Y)	2.38
Change from 52-week high	-1.75%
Change from 52-week low	407.17%
Change from all-time high	-27.32%
Change from all-time low	9,447.37%
Change from open	2.68%
Day's gap	-0.38%
Dollar volume	$56.2M
High price	$73.31
Low price	$70.26
Monthly RSI	84.1
Open price	$70.26
Position in 52-week range	61.8%
Premarket change	-1.74%
Premarket close	$70.53
Premarket price	$69.30
Premarket volume	1.3K
Previous close	$70.53
Price vs 150-day SMA	92.46%
Price vs 20-day SMA	8.51%
Price vs 200-day SMA	119.54%
Price vs 50-day SMA	23.76%
Relative volume	0.59
RSI	69.35
Sharpe ratio	2.5
Sharpe ratio (3Y)	1.48
Sharpe ratio (5Y)	0.35
Sortino ratio	5.79
Sortino ratio (3Y)	2.5
Sortino ratio (5Y)	0.59
Volume	778.6K
Weekly RSI	84.82
YTD price change	285.14%
YTD total return	285.14%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	49.5M
Float percentage	95.6%
Shares change (QoQ)	-3.13%
Shares change (YoY)	-9.45%
Shares held by insiders	4.4%
Shares held by institutions	101.73%
Shares outstanding	51.7M
Short % of float	13.58%
Short % of shares	12.98%
Short ratio	5.2 days

Deeper analysis on CDNA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CDNA report

Is a complete CDNA research report available?

No complete published report is available for CareDx, Inc. (CDNA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

CareDx, Inc. (CDNA)

Price

Financial snapshot

Fair-value bridge

Latest news · CDNA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CDNA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CDNA

Frequently asked questions